Targeted Therapy at the End of Life in Advanced Cancer Patients

Abstract

Objective:

We describe the use of systemic therapy in advanced cancer patients admitted to an acute care hospital, with a focus on targeted therapy. We aim to spotlight the utilization of targeted agents in the last months of life.

Methods:

Adult patients (N=252) with advanced solid tumors who died as inpatients in the National University Hospital, Singapore, were included in this retrospective study. Patients' demographic and clinical data were extracted from hospital records. Information on systemic therapy was extracted from the time of diagnosis and all other data limited to the last three months before death.

Results:

187 adult patients received palliative systemic therapy from the time of diagnosis, of which 125 (66.8%) received it within three months of death. Of patients receiving only nontargeted systemic treatment (n=106), 60 (56.6%) and 26 (24.5%) received it within three months and one month of death respectively. Comparatively, 81 patients received palliative targeted systemic therapy, of which 65 (80.3%) and 40 (49.4%) had treatment within three months and one month of death respectively (p=0.001 and p<0.001). Targeted therapy was first initiated in the last three months of life in 38 patients. Oral agents targeting epidermal growth factor receptor (lung cancer patients) and vascular endothelial growth factor receptor (non–lung cancer patients) pathways were commonly employed. Lung cancer patients were more likely to have targeted therapy as their last line of systemic therapy: 26/54 lung cancer patients compared with 29/133 non–lung cancer patients (48.1% versus 21.8%, p<0.001).

Conclusions:

Targeted therapy is used in more than half of patients who received systemic therapy within three months of death. The degree to which these agents are being utilized near the end of life suggests the need to reexamine the risk/benefit profile of targeted therapy for this population, and the decision-making process around their use.

Get full access to this article

View all access options for this article.

References

Coiffier

, Lepage

, Briere

et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 2002; 346,4:235–242.

Piccart-Gebhart

, Procter

, Leyland-Jones

et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 2005; 353,16:1659–1672.

, Barbera

, Saskin

, Lu

, Neville

, Earle

. Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol, 2011; 29,12:1587–1591.

Wong

, Teo

, Lim

, Wong

, Soo

, Chan

. Targeted therapy at the end of life for patients with lung cancer. J Palliat Med, 2010; 13,8:945–948.

Sledge

Jr.

What is targeted therapy?

J Clin Oncol, 2005; 23,8:1614–1615.

National Registry of Diseases Office (NRDO) of Singapore. www.nrdo.gov.sg/uploadedFiles/NRDO/Cancer_Trends_Report%20_05-09.pdf. 2012 January 26.

Hong

, Chow

, Poulose

et al. Place of death and its determinants for patients with cancer in singapore: An analysis of data from the Singapore cancer registry, 2000–2009. J Palliat Med, 2011; 14,10:1128–1134.

Earle

, Landrum

, Souza

, Neville

, Weeks

, Ayanian

. Aggressiveness of cancer care near the end of life: Is it a quality-of-care issue? J Clin Oncol, 2008; 26,23:3860–3866.

Braga

, Miranda

, Fonseca

et al. The aggressiveness of cancer care in the last three months of life: A retrospective single centre analysis. Psychooncology, 2007; 16,9:863–868.

10.

Yun

, Kwak

, Park

et al. Chemotherapy use and associated factors among cancer patients near the end of life. Oncology, 2007; 72,3–4:164–171.

11.

Nappa

, Lindqvist

, Rasmussen

, Axelsson

. Palliative chemotherapy during the last month of life. Ann Oncol, 2011; 22,11:2375–2380.

12.

Weinstein

. Cancer: Addiction to oncogenes–the Achilles heal of cancer. Science, 2002; 297,5578:63–64.

13.

Wong

, Soong

, Seah

et al. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. J Thorac Oncol, 2008; 3,4:400–404.

14.

Wong

, Seto

, Chin

, Soo

. Lung cancer response to gefitinib, then erlotinib, then gefitinib again. J Thorac Oncol, 2008; 3,9:1077–1078.

15.

Watanabe

, Tanaka

, Ota

et al. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: A retrospective analysis. BMC Cancer, 2011; 11:1.

16.

Moore

, Goldstein

, Hamm

et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 2007; 25,15:1960–1966.

17.

Van Cutsem

, Kohne

, Lang

et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol, 2011; 29,15:2011–2019.

18.

Demetri

, von Mehren

, Blanke

et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002; 347,7:472–480.

19.

Inoue

, Kobayashi

, Usui

et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol, 2009; 27,9:1394–1400.

20.

Langer

. The “lazarus response” in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation. J Clin Oncol, 2009; 27,9:1350–1354.

21.

Maemondo

, Inoue

, Kobayashi

et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010; 362,25:2380–2388.

22.

Mitsudomi

, Morita

, Yatabe

et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol, 2010; 11,2:121–128.

23.

Motzer

, Hutson

, Tomczak

et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol, 2009; 27,22:3584–3590.

24.

Llovet

, Ricci

, Mazzaferro

et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008; 359,4:378–390.

25.

Miles

, Chan

, Dirix

et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol, 2010; 28,20:3239–3247.

26.

Miller

, Wang

, Gralow

et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med, 2007; 357,26:2666–2676.

27.

Robert

, Dieras

, Glaspy

et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol, 2011; 29,10:1252–1260.

28.

Vermorken

, Mesia

, Rivera

et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med, 2008; 359,11:1116–1127.

29.

Braga

. Why do our patients get chemotherapy until the end of life? Ann Oncol, 2011; 22,11:2345–2348.

30.

Chapman

, Hauschild

, Robert

et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 2011; 364,26:2507–2516.

31.

Choi

, Soda

, Yamashita

et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med, 2011; 363,18:1734–1739.

32.

Chabner

. Early accelerated approval for highly targeted cancer drugs. N Engl J Med, 2011; 364,12:1087–1089.

33.

Sleijfer

, Verweij

. The price of success: Cost-effectiveness of molecularly targeted agents. Clin Pharmacol Ther, 2009; 85,2:136–138.

34.

Fishman

, Ten Have

, Casarett

. Cancer and the media: How does the news report on treatment and outcomes? Arch Intern Med, 2010; 170,6:515–518.

35.

Seruga

, Sterling

, Wang

, Tannock

. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol, 2011; 29,2:174–185.

36.

Ocana

, Tannock

. When are “positive” clinical trials in oncology truly positive? J Natl Cancer Inst, 2011; 103,1:16–20.

37.

Harrington

, Smith

. The role of chemotherapy at the end of life: “When is enough, enough?” JAMA, 2008; 299,22:2667–2678.

38.

Saito

, Landrum

, Neville

, Ayanian

, Earle

. The effect on survival of continuing chemotherapy to near death. BMC Palliat Care, 2011; 10:14.

39.

Wong

. Reviewer's report: The effect on survival of continuing chemotherapy to near death. 2010. www.biomedcentral.com/1472-684X/10/14/prepub(last accessed 1/26/2012).

40.

Earle

, Ayanian

. Looking back from death: The value of retrospective studies of end-of-life care. J Clin Oncol, 2006; 24,6:838–840.

41.

Matsuyama

, Reddy

, Smith

. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol, 2006; 24,21:3490–3496.